 COPENHAGEN, Denmark, April 29, 2022 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX Evaxion or the Company, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its first-quarter 2022 financial results on May 11 at 8.30 a.m. EDT. 